FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry. What is described is an anti-Tau phospho Serine 422 (pS422) antibody for treating taupathy, characterised by the fact that it specifically binds to a phosphorylated Tau fragment of the sequence SEQ ID NO:9 and to Tau pS422, and binds to other than Tau and phosphorylated MSAC fragment of the sequence SEQ ID NO:17. What is presented is the pharmaceutical composition for treating taupathy, as well as a method of treating taupathy. What is presented is a method for preparing the above antibody.
EFFECT: invention extends the range of products for treating taupathy.
21 cl, 11 dwg, 7 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
| ANTIBODIES AGAINST CXCR4 | 2017 |
|
RU2748233C2 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617971C2 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617966C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2603078C2 |
| CD43 ANTIBODIES AND USE THEREOF FOR TREATING CANCER | 2016 |
|
RU2694903C1 |
| PHOSPHO-SPECIFIC ANTIBODIES RECOGNIZING TAU | 2012 |
|
RU2639537C2 |
| COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
| ANTI-TAU ANTIBODIES AND METHODS OF USE | 2014 |
|
RU2661111C2 |
| ANTI-IDIOTYPICAL ANTIBODIES THAT INDUCE IMMUNE RESPONSE AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR | 1996 |
|
RU2172636C2 |
